Omega Funds hired its first general counsel months before it raised more than $400 million to invest in the "future of medicine," according to a recent announcement.

Deirdre Cunnane joined the fund in October as general counsel and chief operating officer, according to a news release announcing the additional funding.

A representative for Omega did not respond to request for comment on Monday. Cunnane could not be reached for comment on Monday.

Cunnane most recently served as the chief legal officer of Catabasis Pharmaceuticals Inc. She also served as general counsel at advanced Technology Ventures from 2005 to 2015. She worked as an investment officer at Bank of America, deputy general counsel of BancBoston Capital and as a partner at Goodwin Procter. She graduated from Boston College Law School.

Cunnane was hired in the middle of a fundraising effort. On Dec. 11, Omega announced the closing of Omega Fund VI with $438 million in capital commitments.

"We appreciate the trust from our limited partners and their support of our distinctive investment style, which is guided by our conviction in people, products and breakthrough ideas, not by conventional categories," said Otello Stampacchia, managing director of Omega Funds, in a statement.

Omega Fund was founded in 2004 and is an international investment firm in the life sciences space. The company says it invests in the "world's most urgent medical needs." The fund's portfolio companies brought 37 products to market in areas such as oncology, rare disease and precision medicine, according to the release.

READ MORE: